Answers are grounded in this paper and cite their sources.
Perspective framework proposes bio-biographical response states to explain drug efficacy and toxicity variation, highlighting novel pathways to refine translational pharmacology.
Molecular stratification has improved drug development, yet treatment effects remain heterogeneous within apparently similar patients. We propose that selected lived exposures be studied as bio-biographical response states: prospectively measured combinations of experience, candidate mediator biology, and treatment context that may modify efficacy, toxicity, adherence, or end point ascertainment. This Perspective translates the concept into a falsifiable development framework. It defines pathway-specific hypotheses, consolidates trial-feasible measures, uses immuno-oncology as an implementation test case, and specifies stage-appropriate evidentiary gates. The framework does not treat adversity as destiny or assume that association establishes causation. It requires reliable measurement, formal interaction estimates, competing-explanation analyses, independent replication, and a defined decision consequence. Used with these guardrails, biography can complement molecular pharmacology by revealing reproducible host states that otherwise appear as unexplained response heterogeneity.
No takes yet. Share an insight, caveat, or question.
Baker et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: